| Name | Title | Contact Details |
|---|
Inspectis Digital Microscopes are elegant solutions for modern optical inspection tasks. We manufacture carefully specified Optical Systems for optimum performance, sleekly designed and made from durable high quality materials making them fit for purpose of a long life in real working environments.
The San Francisco Giants are a professional Major League Baseball team in the National League West Division. Founded in 1883 as the New York Gothams, the team became the New York Giants in 1885 and moved to San Francisco in 1958. They play at Oracle Park, known for its stunning waterfront views and unique architecture. The Giants have a rich history, boasting 8 World Series titles, 23 National League pennants, and 9 division titles. The team is owned by Charles B. Johnson and Greg E. Johnson, with Larry Baer as president and Bob Melvin as manager. The organization focuses on providing entertainment through baseball games, merchandise sales, and community programs. They offer various experiences at Oracle Park, including tours and luxury suites, and engage with local fans through youth initiatives and educational outreach. The Giants also produce media content, including broadcasts and archival footage.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We are a trusted leader in providing integrated solutions, leveraging cutting-edge technology to deliver exceptional customer experiences. With a dedicated team and a commitment to excellence, we are redefining industry standards and creating a brighter future for our clients and their customers. Our mission is to make lives better. We engage, listen, and resolve consumer concerns and obligations with empathy and innovation. We advocate for our clients brands and reputations as our own. Follow us, and discover the power of InteLogix.